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ABSTRACT 
Drug delivery systems using colloidal particulate carriers such as liposomes and niosomes have distinct advantages over conventional dosage forms. However, there remain 
significant problems like instability in the general application of liposomes and niosomes for drug delivery. Proniosome have the potential to become a promising drug carrier in 
order to give stability to niosomal drug delivery system without interfering it,s meritorious properties. 
Proniosomes is dry formulation using suitable carrier coated with non ionic surfactants and can be converted into niosomes immediately before use by hydration. 
This article describes the detail of formulation and evaluation of Proniosome including morphology, particle size, particle size distribution and drug release and their advantages 
over noisome. In all parameters proniosome are better than conventional niosomes. 
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INTRODUCTION 
Basic goal of drug therapy is to provide therapeutic amount of drug 
to proper site in body to promptly achieve and then maintain desired 
drug concentration in order to produce desired effect. Recently in the 
field  of  pharmaceutical  sciences  great  efforts  are  being  directed 
towards the refabrication of existing drugs and drug delivery system 
in  to  solve  the  problem  related  to  poor  solubility,  poor 
bioavailability, dosing problem, stability, toxicity etc. This technique 
of  working  has  lead  to  development  of  new  drug  and  new  drug 
delivery system in a more perfect form 
Non ionic surfactant vesicles known as niosomes are gaining great 
attention  as  an  alternative  potential  drugs  delivery  system  to 
conventional liposomes. Niosomes have shown advantages as drug 
carriers,  such as  being  cheap and  chemically  stable  alternative  to 
liposomes, but they are associated with problems related to physical 
stability, such as fusion, aggregation, sedimentation and leakage on 
storage 
1-2. The proniosome approach minimizes these problems by 
using  dry,  free  flowing  product,  which  is  more  stable  during 
sterilization and storage
3.  
Comparison of Proniosome with Niosome 
Niosomes or non-ionic surfactant vesicles are microscopic lamellar 
structure formed on admixture of non ionic surfactant of the alkyl or 
dialkyl polyglycerol ether class and cholesterol with subsequent 
hydration in aqueous media. 
Proniosomes  are  dry  formulations  of  surfactant  coated  carrier 
vesicles.  Proniosomes  are  water  soluble  carrier  particles  that  are 
coated  with  surfactant  and  can  be  hydrated  to  form  niosomal 
dispersion immediately before use on brief agitation in hot aqueous 
media. 
Limitations  of  niosomes  which  can  be  avoided  by  use  of 
proniosomes
4. 
1.  Liposomes and niosomes are dispersed aqueous systems and 
have a problem of degradation by hydrolysis 
2.  Liposomes and niosomes require special storage and handling. 
3.  In liposome purity of natural phospholipids is also variable 
4.  Difficulty in sterilization, transportation, distribution, storage 
uniformity of dose and scale up 
5.  Use of unacceptable solvents of the preparation 
6.  Incomplete hydration of the lipid/surfactant film on the walls 
during hydration process. 
7. Sedimentation, aggregation or fusion on storage is usually seen 
Proniosomes minimize the problems using dry, free flowing product 
which  is  more  stable  during  storage  and  sterilization  and  it  has 
additional  merits  of  easy  of  transfer,  distribution,  measuring  and 
storage. 
Ideal properties of Drug to develop Proniosomes 
1.  Low Aqueous solubility of drugs. 
2.  High dosage frequency of drugs. 
3.  Short half life. 
4.  Controlled drug delivery suitable drugs. 
5.  Higher adverse drug reactions drugs. 
Mechanism of drug transport through skin 
The exact mechanism of penetration of drug in the vesicles through 
the skin is not yet explored, but this is necessary that proniosomes 
should  be  hydrated  to  form  niosomal  vesicles  before  the  drug  is 
released  and  permeates  across  the  skin.  Penetration  depends  on 
nature  and  type  of  the  drug  used,  vesicles  formed  and hydration 
temperature  for  the  conversion  of  proniosomes  to  niosomes. 
Proniosomes  contain  both  non-ionic  surfactant  and  phospholipids 
both  can  act  as  penetration  enhancer  and  useful  in  increasing 
permeation  enhancing.  The  lipids  used  in  the  preparation  of 
proniosomes, act as carrier that will form depot at the site of action 
and  hence  sustains  the  action.  The  rate-limiting  step  in  the 
penetration of drug through the transdermal drug delivery is the lipid 
(ceramides) part of stratum corneum, which packed tightly as bilayer 
by  hydrogen  bonding. The hydrogen  bonding  will  strengthen and 
stabilize  the  lipid  bilayer  and  as  a  result  will  impart  the  barrier 
property of stratum corneum. Proniosomes will hydrate to niosomes 
when applied to skin. On to the skin surface, the niosomes formed 
adsorbs fuses and loosens the ceramides by competitively breaking 
the hydrogen bond network leading to high thermodynamic activity 
at  the  interface  (figure  1).  This  will  increase  the  increases  the 
concentration gradient and hence increases the diffusion pressure for 
the driving of drug through the stratum corneum
5. 
Composition of proniosome  
Main components of Proniosome formulation are following (Figure 
2)  
1. Surfactants 
The term surfactant is a blend of surface active agent. Surfactants 
are usually  organic compounds that are ampiphilic, meaning they 
contain both hydrophobic groups (their tails) and hydrophilic groups 
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insoluble  (and  oil  soluble  component)  and  a  water  soluble 
component. Selection of surfactant should be done on the basis of 
HLB value. Any surfactant, having Hydrophilic Lipophilic Balance 
HLB number in between 4 and 8 was found to be compatible with 
vesicle  formation.  The  encapsulation  efficiency  of  Tween  is 
relatively low as compared to Span
6. 
Nonionic sufactants: 
Examples-Fatty alcohols, Cetyl alcohol, Stearyl alcohol, Cetostearyl 
alcohol,  Oleyl  alcohol,  Polyoxyethylene  glycol  alkyl  ethers  e.g. 
Octaethylene  glycol  monododecyl  ether,  pentaethylene  glycol  , 
Glucoside  alkyl  ethers    eg.  Decyl  glucoside,  Lauryl  glucoside, 
Polyoxyethylene  glycol  alkylphenol  ethers  e.g.  Nonoxynol-9, 
Glycerol alkyl esters: eg.Glyceryl laurate . 
2. Cholesterol 
Steroids  are  important  components  of  cell  membranes  and  their 
presence in membrane brings about significance changes with regard 
to bilayer stability, fluidity, and permeability. Cholesterol a natural 
steroid is the most commonly used membrane additive and can be 
incorporated to bilayers at high molar ratios. It does not form bilayer 
vesicles  but  preven  vesicle  aggregation  by  the  inclusion  of 
molecules  that  stabilize  the  system  against  the  formation  of 
aggregate  by  repulsive  steric  or  electrostatic  effects.  It  leads 
transition from the gel state to liquid phase in noisome systems. As a 
result niosomes becomes less leaky [7]. 
3. Drug 
Entrapment of drug in niosomes increases vesicle size, mainly by 
interaction of solute with surfactant head groups thus increases the 
charge  and  mutual  repulsion  of  the  surfactant  bilayers  and  so 
increases vesicle size
7. 
4. Aqueous Phase 
Phosphate buffer pH 7.4, 0.1% glycerol, hot water are used as 
aqueous phase in preparation of proniosomaes
8. 
5. Solvent 
Alcohol used in Proniosomes has a great effect on vesicle size and 
drug permeation rate 
Solubility of alcohol in water increases the size  in the following 
order
8. 
Ethanol > Propanol > Butanol > Isopropanol 
6. Phosphatidyl choline 
It  acts  as  stabilizing  agent  as  well  as  penetration  enhancer.  The 
commonly used PC is lecithin i.e. soya lecithin, egg lecithin
9. 
Method of Preparation 
1. Slurry method 
Proniosomes can be prepared from a stock solution of surfactants 
and cholesterol in suitable olvent. The required volume of surfactant 
and cholesterol stock solution per gram of carrier and drug should be 
dissolved in the solvent in 100 ml round bottom flask containing the 
carrier  (maltodextrin  or  lecithin).  Additional  chloroform  can  be 
added to form the slurry in case of lower surfactant loading. The 
flask has to be attached to a rotary  flash evaporator to evaporate 
solvent at 50- 60 rpm at a temperature of 45±2
0 C and a reduced 
pressure of 600mm Hg until the mass in the flask had become a dry, 
free flowing product. Finally, the formulation should be stored in 
tightly closed container under refrigeration in light
10. 
2. Coacervation phase separation method 
Accurately  weighed  or  required  amount  of  surfactant,  carrier 
(lecithin), cholesterol and drug can be taken in a clean and dry wide 
mouthed glass vial (5 ml) and solvent should be added to it. All 
these  ingredients  has  to  be  heated  and  after  heating  all  the 
ingredients should be mixed with glass rod. To prevent the loss of 
solvent, the open end of the glass vial can be covered with a lid. It 
has to be warmed over water bath at 60-700 C for 5 minutes until the 
surfactant dissolved completely. The mixture should be allowed to 
cool down at room temperature till the dispersion get converted to a 
proniosomal gel
11. 
3. Slow spray coating method 
A 100 ml round bottom flask containing desired amount of carrier 
can be attached to rotary flash evaporator. A mixture of surfactants 
and cholesterol should be prepared and introduced into round bottom 
flash on rotary evaporator by sequential spraying of aliquots onto 
carrier’s surface. The evaporator has to be evacuated and rotating 
flask can be rotated in water bath under vacuum at 65-70oC for 15 – 
20 min. This process has to be repeated until all of the surfactant 
solution  had  been  applied.  The  evaporation  should  be  continued 
until the powder becomes completely dry
12. 
Formation of Niosomes from Proniosomes  
The niosomes can be prepared from the proniosomes this can be 
achieved by two   ways
13. 
Hydration by skin: The hydration is achieved by skin itself i.e. the 
water in the skin is used to hydrate the proniosome formulation and 
conversion to niosomes.  
Hydration by solvents: Aqueous systems i.e. purified water, saline 
solution and buffers are used to convert proniosomes to niosomes 
with or without agitation and sonication (Figure 3). 
Evaluation of Proniosomes 
1. Stability Studies   
Stability studies carried out by storing the prepared proniosomes at 
various  temperature  conditions  like refrigeration  on  (2-8˚C) room 
temperature (25˚±0.5˚C) and elevated temperature (45˚±0.5˚C) from 
a period of one month to 3 months. Drug content and variation in the 
average  vesicle  diameter  were  periodically  monitored.  ICH 
guidelines  suggests  stability  studies  for  dry  proniosomes  powder 
meant for reconstitution should be studied for accelerated stability at 
75%  relative  humidity  as  per  international  climatic  zones  and 
climatic conditions
14. 
2. Vesicle Size Determination 
It  was  carried  out  using  an  optical  microscopy  with  a  calibrated 
eyepiece  micrometer.  About  200  niosomes  were  measured 
individually, average was taken, and their size range, mean diameter 
were calculated
15. 
3. Drug Content 
Proniosomes  preparation  equivalent  to  40  mg  is  taken  into  a 
standard  volumetric  flask.  Then  they  were  lysed  with  100ml  of 
propane-1-ol by shaking. Then 1ml of this was subsequently diluted 
with phosphate buffer (pH 7.4). The absorbance was measured  by 
UV spectrophotometer
16. 
4. Shape and surface morphology 
Surface morphology means roundness,smoothness and formation of 
aggregation.  it  was  studied  by  screening  electron  microscopy, 
optical microscopy, transmission electron microscopy
16. 
5. Separation of Free Unentrapped Drug 
The  encapsulation  efficiency  of  proniosomes  is  determined  after 
separation of the un- entrapped drug using these techniques: 
A. Dialysis  
The aqueous niosomal dispersion is dialysed tubing against suitable 
dissolution  medium  at  room  temperature  then  samples  are 
withdrawn from the medium at suitable time interval centrifuged and 
analysed for drug content using UV spectroscopy
17. 
B. Gel Filtration  
The free drug is removed by gel filtration of niosomal dispersion 
through a sephadex G50 column and separated with suitable mobile 
phase and analysed by suitable analytical techniques
18. 
C. Centrifugation 
The  niosomal  suspension  is  centrifuged  and  the  surfactant  is 
separated after this the pellet is washed and then re-suspended to 
obtain a niosomal suspension free from unentrapped drug
18. 
6. Drug Entrapment efficiency of proniosomes 
Entrapment efficiency of niosomes can be determined by exhaustive 
dialysis method. The measured quantity of niosomal preparation can 
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was securely attached on one side. The dialysis tube was suspended 
in 100ml phosphate buffer (pH 7.4), which was stirred on a magnetic 
stirrer. The unentrapped drug will get separated from the niosomal 
suspension into the medium through osmosis cellulose membrane. 
At  every  hour  entire  medium  (100ml)  was  replaced  with  fresh 
medium (for about 9-12hrs) till the absorbance reached a constant 
reading indicating no  drug is  available  in unentrapped  form.  The 
niosomal  suspension  in  the  dialysis  tube  was  further  lysed  with 
propane-1-ol  and  estimated  the  entrapped  drug  by  UV 
spectrophotometric  method.  The  entrapment  efficiency  was 
calculated using following equation
19. 
 
 
 
 
 
7. Measurement of Angle of repose 
Proniosomes powder was poured into a funnel which was fixed at a 
position so that the 12mm outlet orifice of the funnel is 5cm above a 
level black surface. The powder flows down from the funnel to form 
a  cone  on  the  surface.  Angle  of  repose  was  then  calculated  by 
measuring the height of the cone and the diameter of its base
20. 
8. Rate of hydration (Spontaneity) 
Spontaneity  of  niosomes  formation  is  described  as  number  of 
niosomes  formed  after  hydration  of  proniosomes  for  15  min. 
Proniosomes  were  transferred to  the  bottom  of  a  small  stoppered 
glass tube and spread uniformly. One ml saline (0.154 M NaCl) was 
added  carefully  along  the  walls  of  the  test  tube  and  kept  aside 
without  agitation.  After  15-20  min  a  drop  of  aqueous  layer  was 
withdrawn  and  placed  on  Neubaur’s  chamber.  The  number  of 
niosomes eluted from proniosomes was counted
20. 
9. Zeta Potential determination 
Zeta potential can be analysed to measure the stability of niosomes 
by  studying  its  colloidal  property.  The  zeta  potential  of 
indomethacin proniosomes was measured by a zeta potential probe. 
Zeta potential analysis is a measure of net charge of niosomes. The 
higher  charge  on  the  surface  of  vesicles  produce  repulsive  force 
between  the  vesicles  which  made  them  stable,  devoid  of 
agglomeration and  faster  settling,  providing  an  evenly  distributed 
suspension
21. 
10. In-vitro drug release and skin permeation studies  
This can be performed by following technique 
(I). Franz Diffusion Cell 
This  franz  diffusion  cell  has  a  donor  chamber  fitted  with  a 
cellophane membrane.the proniosomes are placed in it and dialysed 
against a suitable dissolution medium at room temperature the drug 
content is analyzed using suitable method (UV spectroscopy, HPLC) 
maintenance of sink conditions is essential
22. 
(II). Dialysis Tubing 
This  apparatus  has  prewashed  dialysis  tubing  which  can  be 
hermatically  sealed.the  proniosomes  are  placed  in  it  and  then 
dialyzed  against  a  suitable  dissolution  medium  at  a  room 
temperature the samples are withdrawn from the medium at suitable 
intervals. centrifuged and analyzed for drug content using suitable 
method (UV spectroscopy, HPLC
23. 
(III). Reverse Dialysis 
In this apparatus a no of small dialysis tubes containing 1 ml of 
dissolution medium are  placed.  Then  proniosomes  then  displaced 
into the dissolution medium.the direct dilution of the proniosomes is 
possible  with  this  method.  But  the  rapid  release  can  not  be 
quantified using this method
23. 
11. Drug Release Kinetic Data Analysis  
The release data obtained from various formulations can be studied 
for their fitness of data in different kinetic models like Zero order, 
Higuchi’s and Peppa’s
24. 
1.  Zero order kinetics 
Qt= Q0 + K0t 
Where, Qt = amount of drug dissolved in time t,  
 Q0= initial amount of drug in the solution,  
 K0= Zero order release constant. 
2. First order kinetics 
Log Qt = log Q0 + K1 t/2.303 
Where, Qt = amount of drug released in time t, 
  Q0= initial amount of drug in the solution,  
  K1= first order release rate constant 
3. Higuchi model 
Qt  = KH. t1/2 
Where Qt = amount of drug released in time t, KH= Higuchi 
dissolution constant. 
4. Korsemayer and Peppas release model 
Mt / M∞ = K.tn 
Where, Mt / M∞ = fraction of drug release,  
K = release constant, t = release time,  
n = Diffusion exponent for the drug release that is dependent on the 
slop of the matrix dosage forms. 
CONCLUSION 
Proniosomes are water soluble carrier particles that are coated with 
surfactant  and  can  be  hydrated  to  form  a  niosomal  dispersion 
immediately  before  use  on  brief  agitation  in  hot  aqueous  media. 
Compared  to  liposome  and  niosome  suspension,  proniosome 
represents  a  significant  improvement  by  eliminating  physical 
stability  problems,  such  as  aggregation  or  fusion  of  vesicles  and 
leaking of entrapped drug’s during long term storage. Proniosome 
are  convenient  to  store,  transport  and  for  unit  dosing  since 
proniosome  have  similar  release  characteristics  as  conventional 
niosomes, it may offer improved bioavailability of some drugs with 
poor solubility controlled release formulations or reduced adverse 
effects of some drugs. Because proniosome are a dry powder, further 
processing  is  possible.  To  provide  convenient  unit  dosing,  the 
proniosome  powder  may  be  processed  to  make  beads,  tablets  or 
capsules. The hydration of proniosome powder is much easier than 
the  long  shaking  process  required  to  hydrate  surfactant  in  the 
conventional dry film. 
However,  future  experiments  should  explore  the  suitability  of 
proniosomes with wide variety of drugs having designed drawbacks 
for improved and effective intended therapy. So, that proniosomes 
are  represented  as  promising  drug  carriers  and  promising  drug 
delivery module. 
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Figure1: Mechanism of drug transport from Proniosome through skin  
 
 
 
Figure 2: Composition of Proniosome 
 
 
 
 
Figure 3: Proniosome conversion to Niosome 
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